Other smaller studies investigating other mistletoe preparations are in accordance with our findings ([24-26], for review see [27]) For example in 8 breast cancer patients 10 weeks subcutaneous treatment with 0.2 mg/30 kg of the mistletoe preparation AbnobaViscum Mali (approximately 75 ng/ml/30 kg ML) did not result in systematic changes of IL-6 concentration in supernatants of un-stimulated and stimulated peripheral mononuclear cells before and during treatment compared to baseline [25]. The gene discussed is IL6; the disease is breast cancer.